These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 9126975)
1. CD8Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions. Li L; Sad S; Kägi D; Mosmann TR J Immunol; 1997 May; 158(9):4152-61. PubMed ID: 9126975 [TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity and weak CD40 ligand expression of CD8+ type 2 cytotoxic T cells restricts their potential B cell helper activity. Sad S; Krishnan L; Bleackley RC; Kägi D; Hengartner H; Mosmann TR Eur J Immunol; 1997 Apr; 27(4):914-22. PubMed ID: 9130644 [TBL] [Abstract][Full Text] [Related]
3. Cytokine-deficient CD8+ Tc1 cells induced by IL-4: retained inflammation and perforin and Fas cytotoxicity but compromised long term killing of tumor cells. Sad S; Li L; Mosmann TR J Immunol; 1997 Jul; 159(2):606-13. PubMed ID: 9218575 [TBL] [Abstract][Full Text] [Related]
4. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines. Cerwenka A; Carter LL; Reome JB; Swain SL; Dutton RW J Immunol; 1998 Jul; 161(1):97-105. PubMed ID: 9647212 [TBL] [Abstract][Full Text] [Related]
5. IL-10 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell-induced delayed-type hypersensitivity. Li L; Elliott JF; Mosmann TR J Immunol; 1994 Nov; 153(9):3967-78. PubMed ID: 7930605 [TBL] [Abstract][Full Text] [Related]
6. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy. Jung U; Foley JE; Erdmann AA; Toda Y; Borenstein T; Mariotti J; Fowler DH Biol Blood Marrow Transplant; 2006 Sep; 12(9):905-18. PubMed ID: 16920556 [TBL] [Abstract][Full Text] [Related]
7. Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells. Vinay DS; Kwon BS Cell Immunol; 1999 Feb; 192(1):63-71. PubMed ID: 10066348 [TBL] [Abstract][Full Text] [Related]
8. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL. Fowler DH; Breglio J; Nagel G; Hirose C; Gress RE Biol Blood Marrow Transplant; 1996 Oct; 2(3):118-25. PubMed ID: 9199754 [TBL] [Abstract][Full Text] [Related]
9. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation. Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618 [TBL] [Abstract][Full Text] [Related]
10. Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells. Williams NS; Engelhard VH J Immunol; 1997 Sep; 159(5):2091-9. PubMed ID: 9278294 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. Dobrzanski MJ; Reome JB; Dutton RW J Immunol; 1999 Jun; 162(11):6671-80. PubMed ID: 10352285 [TBL] [Abstract][Full Text] [Related]
12. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. Berner B; Akça D; Jung T; Muller GA; Reuss-Borst MA J Rheumatol; 2000 May; 27(5):1128-35. PubMed ID: 10813277 [TBL] [Abstract][Full Text] [Related]
13. Type 2 immune deviation has differential effects on alloreactive CD4+ and CD8+ T cells. Matesic D; Valujskikh A; Pearlman E; Higgins AW; Gilliam AC; Heeger PS J Immunol; 1998 Nov; 161(10):5236-44. PubMed ID: 9820495 [TBL] [Abstract][Full Text] [Related]
14. Committed memory effector type 2 cytotoxic T (Tc2) cells are ineffective in protective anti-tumor immunity. Do JS; Choi YH; Shin SH; Yi HK; Hwang PH; Nam SY Immunol Lett; 2004 Aug; 95(1):77-84. PubMed ID: 15325801 [TBL] [Abstract][Full Text] [Related]
15. Exposure to T helper 2 cytokines in vivo before encounter with antigen selects for T helper subsets via alterations in antigen-presenting cell function. Cua DJ; Coffman RL; Stohlman SA J Immunol; 1996 Oct; 157(7):2830-6. PubMed ID: 8816386 [TBL] [Abstract][Full Text] [Related]
16. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713 [TBL] [Abstract][Full Text] [Related]
17. Serum cytokine levels and type 1 and type 2 intracellular T cell cytokine profiles in mixed connective tissue disease. Bodolay E; Aleksza M; Antal-Szalmás P; Végh J; Szodoray P; Soltész P; Szegedi A; Szekanecz Z J Rheumatol; 2002 Oct; 29(10):2136-42. PubMed ID: 12375323 [TBL] [Abstract][Full Text] [Related]
18. Tc2 cells respond to soluble antigen in the respiratory tract and induce lung eosinophilia and bronchial hyperresponsiveness. Sawicka E; Noble A; Walker C; Kemeny DM Eur J Immunol; 2004 Sep; 34(9):2599-608. PubMed ID: 15307192 [TBL] [Abstract][Full Text] [Related]
20. [Profiles of type 1 and type 2 T cells in chronic idiopathic thrombocytopenic purpura]. Wang TT; Zhao H; Ren H; Guo JH; Xu MQ; Yang RC; Han ZC Zhonghua Yi Xue Za Zhi; 2006 Mar; 86(10):669-73. PubMed ID: 16681922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]